Cervical Cancer

>

Latest News

Results from the phase 3 KEYNOTE-826 trial show that the safety profile of pembrolizumab plus chemotherapy was manageable in cervical cancer.
Pembrolizumab Plus Chemotherapy Improves OS, PFS in Cervical Cancer

December 17th 2024

Results from the phase 3 KEYNOTE-826 trial show that the safety profile of pembrolizumab plus chemotherapy was manageable in cervical cancer.

Data from the INTERLACE trial shows induction chemotherapy followed by chemoradiotherapy prolongs overall survival in locally advanced cervical cancer.
Induction Chemotherapy Combination Boosts PFS/OS in Cervical Cancer

November 3rd 2024

Subgroup data indicate a positive efficacy trend for TG4001 plus avelumab among patients with cervical cancer.
Cancer Vaccine Combo Does Not Improve PFS in Cervical/Anogenital Tumors

October 15th 2024

Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer
Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer

September 25th 2024

Pembrolizumab/CRT Improve Survival in High-Risk Locally Advanced Cervical Cancer
Pembrolizumab/CRT Improve Survival in High-Risk Locally Advanced Cervical Cancer

September 14th 2024

Latest CME Events & Activities

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances

View More

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

View More

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

View More

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

View More

<1
...
89101112